From the Journals

ADHD rates holding steady in U.S. children


 

TOPLINE:

While the prevalence of attention-deficit/hyperactivity disorder in U.S. children increased from the late 1990s to 2016, more recent data show rates remained steady at around 10% from 2017 to 2022.

METHODOLOGY:

  • Based on prior data, the prevalence of ADHD in children rose from 6.1% in 1997-1998 to 10.2% in 2015-2016, with a 42.0% increase from 2003 to 2011. The new report provides updated prevalence data for 2017-2022.
  • The cross-sectional analysis used data from the National Health Interview Survey (NHIS) from 2017 to 2022 for more than 37,609 U.S. children and adolescents 4-17 years old (52% male, 53% non-Hispanic White, 24% Hispanic, 11% non-Hispanic Black, and 12% non-Hispanic other race).
  • Information on health care provider–diagnosed ADHD was reported by a parent or guardian.

TAKEAWAY:

  • A total of 4,098 children and adolescents (10.9%) were reported to have an ADHD diagnosis during the study period.
  • The weighted prevalence of ADHD ranged from 10.08% to 10.47% from 2017 to 2022, which is similar to the prevalence in 2015-2016 (10.20%).
  • There was no significant change on an annual basis or in all subgroups evaluated. Notably, the estimated prevalence of ADHD among U.S. children and adolescents was higher than worldwide estimates (5.3%) in earlier years (1978-2005).
  • The prevalence of ADHD in U.S. children differed significantly by age, sex, race/ethnicity, and family income, in line with previous findings, with higher rates in those 12-17 years (vs. 4-11 years), males, non-Hispanic populations, and those with higher family income.

IN PRACTICE:

The estimated ADHD prevalence remains “high” and “further investigation is warranted to assess potentially modifiable risk factors and provide adequate resources for treatment of individuals with ADHD in the future,” the authors write.

SOURCE:

The study, with first author Yanmei Li, Guangdong Pharmaceutical University, Guangzhou, China, was published online in JAMA Network Open.

LIMITATIONS:

Information on ADHD relied on parent-reported diagnosis, which may lead to misreporting and recall bias. The NHIS underwent a major redesign in 2019, which may affect comparability with prior years, and the COVID-19 pandemic affected collection in 2020.

DISCLOSURES:

The study had no specific funding. The authors reported no relevant financial relationships.

A version of this article first appeared on Medscape.com.

Recommended Reading

Once-daily stimulant for ADHD safe, effective at 1 year
MDedge Pediatrics
Walnuts linked to improved attention, psychological maturity in teens
MDedge Pediatrics
Most children with ADHD are not receiving treatment
MDedge Pediatrics
FDA moves to curb misuse of ADHD meds
MDedge Pediatrics
Family placement better for deprived kids than institutions
MDedge Pediatrics
Tips for addressing uptick in mental health visits: Primary care providers collaborate, innovate
MDedge Pediatrics
Nonstimulants: A better option for ADHD?
MDedge Pediatrics
Reassuring data on stimulants for ADHD in kids and later substance abuse
MDedge Pediatrics
Nutritional psychiatry: Does it exist?
MDedge Pediatrics
Surge in pediatric ADHD med errors prompts call for prevention
MDedge Pediatrics